Expert Practices in Hidradenitis Suppurativa Flare Management: A Cross-Sectional Survey Study.

Autor:	Masson R; Keck School of Medicine of USC, University of Southern CA, Los Angeles, CA, USA., Park S; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Shi VY; Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock, AR, USA., Hsiao JL; Department of Dermatology, University of Southern CA, Los Angeles, CA, USA., Aleshin MA; Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA.
Jazyk:	angličtina
Zdroj:	Skin appendage disorders [Skin Appendage Disord] 2024 Jun; Vol. 10 (3), pp. 224-228. Date of Electronic Publication: 2024 Jan 24.
DOI:	10.1159/000536094
Abstrakt:	Introduction: Hidradenitis suppurativa (HS) is a chronic skin condition with recurrent, debilitating flares. Although the majority of patients with HS endorse flares, there is a lack of research regarding HS experts' flare management practices and perspectives. Methods: An anonymous online survey was distributed through an HS expert listserv. Board-certified dermatologists who saw 1 or more HS patient(s) per month were eligible for participation. Results: A total of 35 responses were collected; 97.1% self-identified as HS experts. Therapies used for HS flares by more than two-thirds of the respondents included systemic antibiotics (100%), nonprescription pain relievers (91.4%), intralesional triamcinolone injections (91.4%), prescription pain relievers (71.4%), oral corticosteroids (68.6%), and warm compresses (68.6%). The top 3 dermatologist-reported barriers that patients face in accessing care during flares include lack of clinic appointment availability (88.6%), distance that patients have to travel to reach clinic (85.7%), and lack of transportation for patients (62.9%). Conclusions: Overall, this study highlights variations in the ways that HS experts manage flares. Many of the treatment modalities used by the majority of respondents are not part of the official North American guidelines. Further prospective studies and expert consensus guidelines are needed to standardize the approach to flare management. Competing Interests: V.Y.S. is on the board of directors for the Hidradenitis Suppurativa Foundation (HSF), an advisor for the National Eczema Association, is a stock shareholder of Learn Health, and has served as an advisory board member, investigator, speaker, and/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Genentech, Eli Lilly, Novartis, SUN Pharma, LEO Pharma, Pfizer, Incyte, Boehringer Ingelheim, Alumis Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt’s Bees, Galderma, Kiniksa, UCB, Target PharmaSolutions, Altus Laboratories/CQuell, MYOR, Polyfins Technology, GpSkin, and Skin Actives Scientific. J.L.H. is on the Board of Directors for the Hidradenitis Suppurativa Foundation and has served as a consultant for AbbVie, Aclaris, Boehringer Ingelheim, Novartis, as a speaker for AbbVie, and as an investigator for Amgen, Aristea, Boehringer Ingelheim, and Incyte. M.A.A. has served as a consultant for AbbVie, Novartis, Santa Ana Bio and has received research funding from UCB. All other authors report no conflicts of interest. (© 2024 The Author(s). Published by S. Karger AG, Basel.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu